Treatment Information

Back

Prostate Cancer treatment details. Chemotherapy.

Taussig Cancer Center, The Cleveland Clinic Foundation, Cleveland, Ohio, United States.

Survival: monthsCountry:United States
Toxiciy Grade:3City/State/Province:Cleveland, Ohio
Treatments:ChemotherapyHospital:Taussig Cancer Center, The Cleveland Clinic Foundation
Drugs:Journal:Link
Date:Jan 2005

Description:

Patients: This Phase II study involved 39 patients with hormone refractory prostate cancer. The median age was 69 years and the median PSA was 117.7 (range 4.3 – 1497.8). Thirty-three patients had bone metastases and all patients had received prior hormone therapy.

Treatment: The treatment consisted of a new chemotherapy drug called satraplatin (JM-216).

Toxicity: Seventeen patients had a total of 35 hospitalizations. Twelve of these hospitalizations were believed to be related to JM-216. Grade 3 or higher toxicities included hematologic, diarrhea, vomiting, nausea, and elevated liver enzymes.

Results: The median survival was 16.7 months.

Correspondence: David Peereboom, MD




Back